Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Executive Summary
Dr. Reddy's omeprazole case against FDA challenges the agency's decision to award exclusivity on a patent-by-patent basis
You may also be interested in...
Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity
Schwarz Pharma is exploring a scenario where it would win a favorable decision in the Prilosec patent case, while generic omeprazole marketing exclusivity holder Andrx loses on non-infringement
Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity
Schwarz Pharma is exploring a scenario where it would win a favorable decision in the Prilosec patent case, while generic omeprazole marketing exclusivity holder Andrx loses on non-infringement
AstraZeneca Prilosec Patent Litigation Decision By Mid-Year, Andrx Says
Andrx expects a decision regarding AstraZeneca's Prilosec (omeprazole) patent litigation by mid-year